29 completed, 8 terminated, 1 active not recruiting, 1 recruiting. 15 Phase 1, 14 Phase 3, 10 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 11, Terminated 4 |
| Phase 3 | 14 | Completed 10, Terminated 4 |
| Phase 2 | 10 | Completed 5, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Mundipharma Research Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options Rezafungin Acetate - Chronic Pulmonary Aspergillosis | Phase 2 | Active not recruiting | Mundipharma Research Limited | 60 | 2025-06-30 | 2026-05-14 |
| Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults Co-Trimoxazole, Rezafungin Acetate / Co Trimoxazole - Pneumocystis Pneumonia | Phase 2 | Recruiting | Mundipharma Research Limited | 50 | 2023-11-14 | 2025-04-03 |
| Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age Rezafungin Acetate - Invasive Fungal Infections | Phase 1 | Terminated | Mundipharma Research Limited | 32 | 2023-09-13 | 2025-04-06 |
| Study of Tinostamustine for Adjuvant Treatment of Glioblastoma Tinostamustine - Glioblastoma Multiforme | Early Phase 1 | Completed | Mundipharma Research Limited | 10 | 2022-07-01 | 2025-12-10 |
| European Cohort Study of the Effectiveness of Take Home Naloxone Naloxone - Opioid Overdose | Unknown | King's College London | 6000 | 2021-06-08 | 2023-03-29 | |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Continuous Monitoring of Physiology and Self-reported Pain Score Amongst Post-surgical Knee Patients Continuous physiology monitoring in ambulatory setting pre and post surgery - Knee Arthroplasty | Completed | Biofourmis Singapore Pte Ltd. | 55 | 2019-02-02 | 2022-10-27 | |
| Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min - Small Cell Lung Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Mundipharma Research Limited | 71 | 2017-11-08 | 2024-10-21 |
| A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils fluticasone propionate/formoterol fumarate breath actuated inhaler, Indacaterol maleate / glycopyrronium bromide capsules - ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) | Phase 2 / Phase 3 | Terminated | Mundipharma Research Limited | 2 | 2016-07-01 | 2016-12-12 |
| A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma Fluticasone/Formoterol BAI, Fluticasone/Vilanterol DPI (Relvar Ellipta DPI) - Asthma | Phase 3 | Completed | Mundipharma Research Limited | 105 | 2016-06-15 | 2018-10-23 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Tinostamustine - Hematological Malignancies, Multiple Myeloma | Phase 1 | Completed | Mundipharma Research Limited | 106 | 2016-04-14 | 2024-07-25 |
| Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution MR902, IR morphine sulphate - Opioid Substitution Treatment | Phase 1 | Completed | Mundipharma Research Limited | 84 | 2015-09-01 | 2016-05-16 |
| A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication MRXXX, MR1XXX, MR2XXX - Pain | Phase 1 | Completed | Mundipharma Research Limited | 32 | 2015-04-01 | 2017-08-31 |
| An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion BTDS - Pain | Phase 1 | Completed | Mundipharma Research Limited | 40 | 2015-03-01 | 2016-02-09 |
| A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia | Phase 2 | Completed | Light Sciences Oncology | 225 | 2014-11-01 | 2018-08-08 |
| Bioequivalence and Adhesion Comparison of Buprenorphine Patches Buprenorphine - Pain | Phase 1 | Completed | Mundipharma Research Limited | 104 | 2014-10-01 | 2016-02-09 |
| Flutiform® Compared With Seretide® in the Treatment of COPD Flutiform 500/20 µg BID, Flutiform 250/10 µg BID, Seretide Accuhaler 50/500 µg BID - Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Completed | Mundipharma Research Limited | 923 | 2014-09-01 | 2017-03-28 |
| A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers Fluticasone/formoterol BAI, Formoterol, Fluticasone/formoterol PMDI without spacer - Asthma | Phase 1 | Completed | Mundipharma Research Limited | 125 | 2014-08-01 | 2015-09-28 |
| A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches Second generation BTDS patch, First generation BuTrans patch - Pain | Phase 1 | Completed | Mundipharma Research Limited | 20 | 2014-05-01 | 2014-09-30 |
| A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State. 4 mg 12 hourly capsule - strong pain killer fasted, 4 mg 12 hourly capsule - strong pain killer fed, 12 hourly capsule strong painkiller with antagonist fasted) - Pain | Phase 1 | Completed | Mundipharma Research Limited | 16 | 2014-04-01 | 2014-06-27 |
Showing 20 of 40. Sign in to see all of them.
Asthma (10) · Pain (6) · Pulmonary Disease, Chronic Obstructive (4) · Invasive Fungal Infections (2) · Pneumonia, Pneumocystis (2) · Recurrence (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Cancer Pain (1) · Candidemia (1) · Candidiasis (1) · Candidiasis, Invasive (1) · Chronic Pain (1) · Death (1) · Drug Overdose (1)
Fluticasone (10) · fluticasone-formoterol (8) · Formoterol Fumarate (6) · Rezafungin (4) · tinostamustine (3) · Buprenorphine (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · forodesine (2) · BID protein, human (1) · Budesonide (1) · Fluconazole (1) · Fluticasone-Salmeterol Drug Combination (1) · Glycopyrrolate (1) · Injections (1) · Metered Dose Inhalers (1)
United Kingdom (22) · Germany (10) · Spain (8) · Hungary (7) · France (5) · Italy (5) · Poland (5) · Romania (5) · Netherlands (4) · Slovakia (4) · United States (4) · Australia (3) · Austria (3) · Bulgaria (3) · Czechia (3)
Alison Chisholm, MSc (1) · Ana Oaknin, MD (1) · David Price, Prof. MD (1) · Laura Cox, PhD (1) · Lisa Koch-Hulle (1) · Mohit Joshi, MD (1) · Pier L Zinzani, MD,PhD (1) · Prof Sir John Strang (1) · Shivaani Kummar, MD (1) · Tomas Janik, MD (1)
PMID 21196104, PMID 21605396, PMID 23081745, PMID 23368897, PMID 26474679, PMID 26547914, PMID 28683212, PMID 29256049, PMID 33438477, PMID 36472162, PMID 37612698, PMID 37773627, PMID 39617826, PMID 41151592, PMID 42438068
2008 (3), 2014 (3), 2009 (2), 2015 (1), 2017 (1)